Metabolic disease biotechnology is the fastest-growing therapeutic area in the biopharmaceutical industry. GLP-1 receptor agonists have transformed obesity from a poorly-treated chronic condition to a rapidly-growing pharmaceutical market worth over $50 billion by 2030. The extension of GLP-1 indications beyond diabetes and obesity — cardiovascular risk reduction, heart failure, sleep apnea, kidney disease, NASH — is expanding the addressable patient population to hundreds of millions globally. Novo Nordisk's semaglutide franchise dominates the space but faces intensifying competition from Eli Lilly's tirzepatide and next-generation agents from Amgen, Pfizer, and others.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• GLP-1 Market Dynamics
• Obesity Drug Development
• NASH
• MASH Therapeutic Landscape
• Cardiovascular Risk Reduction Biologics
• Diabetes Biologic Therapy
• Novo Nordisk vs. Eli Lilly Competition
• Next-Generation Metabolic Disease Pipeline
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. GLP-1 Market Dynamics
4. Obesity Drug Development
5. NASH
6. MASH Therapeutic Landscape
7. Cardiovascular Risk Reduction Biologics
8. Diabetes Biologic Therapy
9. Novo Nordisk vs. Eli Lilly Competition
10. Next-Generation Metabolic Disease Pipeline
11. Competitive Landscape
12. Competitive Landscape
13. Regional Market Analysis
14. Strategic Conclusions
15. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. GLP-1 Market Dynamics
Table 3. Obesity Drug Development
Table 4. NASH
Table 5. MASH Therapeutic Landscape
Table 6. Cardiovascular Risk Reduction Biologics
Table 7. Diabetes Biologic Therapy
Table 8. Novo Nordisk vs. Eli Lilly Competition
Table 9. Next-Generation Metabolic Disease Pipeline
Table 10. Competitive Landscape
Table 11. Leading Companies — Strategy Assessment 2025
Table 12. Pipeline Assessment 2025
Table 13. Key Risks and Mitigation Strategies
Companies Profiled
Novo Nordisk
Eli Lilly
Sanofi
AstraZeneca
Pfizer
Roche
Viking Therapeutics
Structure Therapeutics
